General Information of Drug Off-Target (DOT) (ID: OT0RTR7M)

DOT Name Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15)
Synonyms
12/15-lipoxygenase; Arachidonate 12-lipoxygenase, leukocyte-type; 12-LOX; EC 1.13.11.31; Arachidonate 15-lipoxygenase; 15-LOX; 15-LOX-1; EC 1.13.11.33; Arachidonate omega-6 lipoxygenase; Hepoxilin A3 synthase Alox15; EC 1.13.11.-; Linoleate 13S-lipoxygenase; EC 1.13.11.12
Gene Name ALOX15
Related Disease
Pregnancy loss, recurrent, susceptibility ( )
UniProt ID
LOX15_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
1.13.11.-; 1.13.11.12; 1.13.11.31; 1.13.11.33
Pfam ID
PF00305 ; PF01477
Sequence
MGLYRIRVSTGASLYAGSNNQVQLWLVGQHGEAALGKRLWPARGKETELKVEVPEYLGPL
LFVKLRKRHLLKDDAWFCNWISVQGPGAGDEVRFPCYRWVEGNGVLSLPEGTGRTVGEDP
QGLFQKHREEELEERRKLYRWGNWKDGLILNMAGAKLYDLPVDERFLEDKRVDFEVSLAK
GLADLAIKDSLNVLTCWKDLDDFNRIFWCGQSKLAERVRDSWKEDALFGYQFLNGANPVV
LRRSAHLPARLVFPPGMEELQAQLEKELEGGTLFEADFSLLDGIKANVILCSQQHLAAPL
VMLKLQPDGKLLPMVIQLQLPRTGSPPPPLFLPTDPPMAWLLAKCWVRSSDFQLHELQSH
LLRGHLMAEVIVVATMRCLPSIHPIFKLIIPHLRYTLEINVRARTGLVSDMGIFDQIMST
GGGGHVQLLKQAGAFLTYSSFCPPDDLADRGLLGVKSSFYAQDALRLWEIIYRYVEGIVS
LHYKTDVAVKDDPELQTWCREITEIGLQGAQDRGFPVSLQARDQVCHFVTMCIFTCTGQH
ASVHLGQLDWYSWVPNAPCTMRLPPPTTKDATLETVMATLPNFHQASLQMSITWQLGRRQ
PVMVAVGQHEEEYFSGPEPKAVLKKFREELAALDKEIEIRNAKLDMPYEYLRPSVVENSV
AI
Function
Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. It inserts peroxyl groups at C12 or C15 of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) producing both 12-hydroperoxyeicosatetraenoate/12-HPETE and 15-hydroperoxyeicosatetraenoate/15-HPETE. It may then act on 12-HPETE to produce hepoxilins, which may show pro-inflammatory properties. Can also peroxidize linoleate ((9Z,12Z)-octadecadienoate) to 13-hydroperoxyoctadecadienoate/13-HPODE. May participate in the sequential oxidations of DHA ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate) to generate specialized pro-resolving mediators (SPMs)like resolvin D5 ((7S,17S)-diHPDHA) and (7S,14S)-diHPDHA, that actively down-regulate the immune response and have anti-aggregation properties with platelets. Can convert epoxy fatty acids to hydroperoxy-epoxides derivatives followed by an intramolecular nucleophilic substitution leading to the formation of monocyclic endoperoxides. Plays an important role during the maintenance of self-tolerance by peroxidizing membrane-bound phosphatidylethanolamine which can then signal the sorting process for clearance of apoptotic cells during inflammation and prevent an autoimmune response. In addition to its role in the immune and inflammatory responses, this enzyme may play a role in epithelial wound healing in the cornea through production of lipoxin A4 (LXA(4)) and docosahexaenoic acid-derived neuroprotectin D1 (NPD1; 10R,17S-HDHA), both lipid autacoids exhibit anti-inflammatory and neuroprotective properties. Furthermore, it may regulate actin polymerization which is crucial for several biological processes such as the phagocytosis of apoptotic cells. It is also implicated in the generation of endogenous ligands for peroxisome proliferator activated receptor (PPAR-gamma), hence modulating macrophage development and function. It may also exert a negative effect on skeletal development by regulating bone mass through this pathway. As well as participates in ER stress and downstream inflammation in adipocytes, pancreatic islets, and liver. Finally, it is also involved in the cellular response to IL13/interleukin-13.
Tissue Specificity Detected in monocytes and eosinophils (at protein level). Expressed in airway epithelial cells.
KEGG Pathway
Arachidonic acid metabolism (hsa00590 )
Linoleic acid metabolism (hsa00591 )
Metabolic pathways (hsa01100 )
Efferocytosis (hsa04148 )
Ferroptosis (hsa04216 )
Necroptosis (hsa04217 )
Serotonergic sy.pse (hsa04726 )
Reactome Pathway
Synthesis of 12-eicosatetraenoic acid derivatives (R-HSA-2142712 )
Synthesis of 15-eicosatetraenoic acid derivatives (R-HSA-2142770 )
Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807 )
Biosynthesis of DHA-derived SPMs (R-HSA-9018677 )
Biosynthesis of protectins (R-HSA-9018681 )
Biosynthesis of E-series 18(S)-resolvins (R-HSA-9018896 )
Biosynthesis of E-series 18(R)-resolvins (R-HSA-9023661 )
Biosynthesis of DPAn-6 SPMs (R-HSA-9025106 )
Biosynthesis of DPAn-3-derived protectins and resolvins (R-HSA-9026286 )
Synthesis of Leukotrienes (LT) and Eoxins (EX) (R-HSA-2142691 )
BioCyc Pathway
MetaCyc:HS08621-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Pregnancy loss, recurrent, susceptibility DISHILEF Limited Autosomal recessive [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Biotransformations of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Linoleic acid DMDGPY9 Investigative Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15) increases the oxidation of Linoleic acid. [17]
------------------------------------------------------------------------------------
3 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [2]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [13]
Bisphenol A DM2ZLD7 Investigative Bisphenol A affects the methylation of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [15]
------------------------------------------------------------------------------------
14 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Tretinoin DM49DUI Approved Tretinoin affects the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [3]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [4]
Quercetin DM3NC4M Approved Quercetin decreases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [5]
Vorinostat DMWMPD4 Approved Vorinostat increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [6]
Triclosan DMZUR4N Approved Triclosan increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [7]
Sulindac DM2QHZU Approved Sulindac increases the activity of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [8]
3,4-Dihydroxycinnamic Acid DMVZL26 Phase 4 3,4-Dihydroxycinnamic Acid decreases the activity of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [9]
EXISULIND DMBY56U Phase 3 EXISULIND increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [10]
BAICALEIN DM4C7E6 Phase 2 BAICALEIN decreases the activity of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [11]
CP-461 DMEYMTX Phase 2 CP-461 increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [12]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [14]
NS398 DMINUWH Terminated NS398 increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [10]
HONOKIOL DMJWT3X Investigative HONOKIOL increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [16]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Investigative (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol increases the expression of Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15). [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Drug(s)

References

1 Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
2 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
3 Expression of 15-lipoxygenase-1 in human nasal epithelium: its implication in mucociliary differentiation. Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):77-83. doi: 10.1016/j.plefa.2005.05.023.
4 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
5 Different roles of Nrf2 and NFKB in the antioxidant imbalance produced by esculetin or quercetin on NB4 leukemia cells. Chem Biol Interact. 2018 Oct 1;294:158-166.
6 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004 Dec 1;64(23):8778-81.
7 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
8 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 Jul 19;92(14):1136-42.
9 Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 2001 Jun 15;61(12):4879-84.
10 GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res. 2002 Feb 15;62(4):1178-83.
11 Evaluation of the antioxidative properties of lipoxygenase inhibitors. Pharmacol Rep. 2012;64(5):1179-88.
12 Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res. 2005 Sep 15;65(18):8442-7.
13 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
14 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
15 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
16 Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br J Pharmacol. 2010 Aug;160(8):1963-72.
17 Bongkrekic acid as a selective activator of the peroxisome proliferator-activated receptor (PPAR) isoform. J Toxicol Sci. 2015 Apr;40(2):223-33. doi: 10.2131/jts.40.223.